Company News

Sulforadex Licensed for Pharmaceutical Development

Visit Lalilab (Booth No. 662) to learn more about its topical applications.

Author Image

By: TOM BRANNA

Editor

Evgen Limited, has exercised its option with Lalilab and PharmAgra Labs to enter into a worldwide exclusive license agreement to develop Sulforadex as an oral pharmaceutical for the prevention and treatment of prostate cancer and other cancers. Concurrently, Lalilab (Booth No. 662) and PharmAgra retain the rights to develop the patented stabilized sulforaphane technology for topical applications; focusing on skin disease, therapeutics and cosmetics. In this regard, they are currently working ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters